Surrozen (NASDAQ:SRZN) Director Tim Kutzkey Acquires 5,523 Shares

Surrozen, Inc. (NASDAQ:SRZN) Director Tim Kutzkey bought 5,523 shares of Surrozen stock in a transaction that occurred on Wednesday, January 14th. The stock was purchased at an average cost of $19.99 per share, with a total value of $110,404.77. Following the completion of the transaction, the director owned 999,429 shares of the company’s stock, valued at $19,978,585.71. This trade represents a 0.56% increase in their ownership of the stock. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link.

Tim Kutzkey also recently made the following trade(s):

• On Tuesday, January 13th, Tim Kutzkey acquired 12,470 shares of Surrozen stock. The stock was acquired at an average price of $19.80 per share, with a total value of $246,906.00.
• On Tuesday, January 6th, Tim Kutzkey bought 15,100 shares of Surrozen stock. The shares were acquired at an average price of $19.89 per share, for a total transaction of $300,339.00.
• On Friday, December 5th, Tim Kutzkey bought 30,884 shares of Surrozen stock. The stock was acquired at an average cost of $19.54 per share, for a total transaction of $603,473.36.
• On Thursday, December 4th, Tim Kutzkey purchased 5,266 shares of Surrozen stock. The shares were acquired at an average price of $17.35 per share, with a total value of $91,365.10.
• On Thursday, November 13th, Tim Kutzkey acquired 315,457 shares of Surrozen stock. The shares were bought at an average cost of $12.65 per share, for a total transaction of $3,990,531.05.

Surrozen Price Performance

Shares of SRZN stock remained flat at $20.00 during trading hours on Thursday. The stock had a trading volume of 28,721 shares, compared to its average volume of 83,852. Surrozen, Inc. has a 52 week low of $5.90 and a 52 week high of $24.94. The company has a market cap of $171.40 million, a price-to-earnings ratio of -0.90 and a beta of 0.58. The stock’s 50 day moving average is $18.38 and its two-hundred day moving average is $13.80.

Surrozen (NASDAQ:SRZN) last announced its quarterly earnings results on Friday, November 7th. The company reported ($3.61) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.17) by ($2.44). Surrozen had a negative net margin of 2,909.10% and a negative return on equity of 4,055.04%. The company had revenue of $0.98 million during the quarter. On average, research analysts expect that Surrozen, Inc. will post -8.49 earnings per share for the current fiscal year.

Analysts Set New Price Targets

SRZN has been the topic of a number of recent analyst reports. Weiss Ratings restated a “sell (d-)” rating on shares of Surrozen in a research report on Wednesday, October 8th. Lifesci Capital raised Surrozen to a “strong-buy” rating in a report on Thursday, November 13th. Finally, Wall Street Zen upgraded Surrozen to a “sell” rating in a research report on Friday, November 28th. One research analyst has rated the stock with a Strong Buy rating, one has assigned a Buy rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus price target of $32.00.

Institutional Trading of Surrozen

A number of hedge funds and other institutional investors have recently modified their holdings of the stock. Woodline Partners LP bought a new position in Surrozen in the 3rd quarter worth approximately $621,000. Millennium Management LLC acquired a new stake in shares of Surrozen in the 3rd quarter valued at $1,414,000. Citadel Advisors LLC raised its position in shares of Surrozen by 32.8% during the third quarter. Citadel Advisors LLC now owns 13,875 shares of the company’s stock worth $179,000 after acquiring an additional 3,424 shares during the last quarter. Schonfeld Strategic Advisors LLC bought a new stake in shares of Surrozen during the third quarter worth $889,000. Finally, Acuta Capital Partners LLC lifted its stake in shares of Surrozen by 5.0% during the third quarter. Acuta Capital Partners LLC now owns 178,415 shares of the company’s stock valued at $2,299,000 after acquiring an additional 8,415 shares during the period. Institutional investors and hedge funds own 66.57% of the company’s stock.

About Surrozen

Surrozen, Inc is a clinical-stage biopharmaceutical company focused on developing novel therapeutic antibodies that target the Wnt signaling pathway for applications in tissue repair, regeneration and oncology. Founded in 2012 and headquartered in South San Francisco, California, the company leverages its proprietary SurroBody platform to design bispecific antibody molecules capable of modulating Wnt receptor activity with enhanced tissue specificity.

The SurroBody platform enables the generation of high-affinity, dual-binding antibodies engineered to either activate or inhibit Wnt signaling, a pathway critical to cell proliferation, differentiation and homeostasis.